Mepicain

Mepivacaine Hydrochloride, the active ingredient in Mepicain, is a local anesthetic (amide type) presented as a sterile solution for intravenous use. It provides rapid onset of sensory nerve block for dental, minor surgical and diagnostic procedures in adult patients.

GNH USA supplies Mepicain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mepicain is a local anesthetic used to achieve temporary loss of sensation in specific tissues during minor procedures. - Dental procedures: provides analgesia for extractions, restorations and periodontal surgery. - Minor surgical procedures: facilitates anesthesia for skin suturing, biopsy and minor excisions. - Diagnostic procedures requiring local anesthesia: enables patient comfort during endoscopy, catheter placement and similar interventions.

Mepicain may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Transient tingling or numbness at the injection site - Mild dizziness or light‑headedness - Temporary increase in heart rate - Mild nausea or vomiting - Localized swelling or erythema

Serious or Rare Side Effects: - Allergic reaction (rash, pruritus, bronchospasm, anaphylaxis) - Central nervous system toxicity (seizures, tremors, loss of consciousness) - Cardiovascular toxicity (arrhythmias, hypotension, cardiac arrest) - Methemoglobinemia - Persistent paresthesia or nerve injury

Before using Mepicain, clinicians should assess patient history and monitor for potential complications. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: avoid in patients with severe conduction disorders or uncontrolled arrhythmias. - Neurological conditions: use cautiously in patients with epilepsy or other seizure disorders. - Drug interactions: review concomitant medications that may affect cardiac or CNS function. - Pregnancy and lactation: consider risk‑benefit ratio; use only if clearly needed. - Store below 25°C: keep in the original container, protect from light and moisture.

Mepicain can interact with other agents that influence cardiac conduction or central nervous system activity.

Major Interactions (Avoid): - Class I anti‑arrhythmic drugs (e.g., quinidine, procainamide): may potentiate cardiotoxicity. - Monoamine oxidase inhibitors (MAOIs): increase risk of severe hypertension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may exacerbate bradycardia. - CNS depressants (e.g., benzodiazepines, opioids): enhance sedation and respiratory depression. - Other local anesthetics: cumulative toxicity risk. - Diuretics: may alter plasma protein binding, affecting drug levels.